Skip to content

Previous poor adherence and HCV are risk factors for antiretroviral treatment failure

TB-related immune reaction to HIV therapy occurs 20 months after TB treatment first started - is this a record?

Triple nuke combination of AZT/3TC/tenofovir below current standards as a first-line regimen

HIV treatment may need to start above 300 CD4s in HIV/hepatitis C coinfected, study suggests

Kaletra monotherapy: ultra-sensitive tests find viral loads comparable to triple combination therapy

Is genetic screening for abacavir hypersensitivity risk appropriate for black Africans?

HPA 2006 analysis: HIV in the UK 'a major public health concern' and 'substantial challenge'

Tipranavir falls between two stools in naïve trial

Boosted saquinavir has similar potency, better lipid profile than lopinavir/r in naïve patients: interim results from GEMINI study